Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis.

@article{Farkas2016EfficacyOI,
  title={Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis.},
  author={Klaudia Farkas and Mariann Rutka and Petra Anna Golovics and Zsuzsanna V{\'e}gh and Barbara Dorottya Lov{\'a}sz and Tibor Andr{\'a}s Ny{\'a}ri and Krisztina Barbara Gecse and Martin Bortlik and Martin Bortl{\'i}k and Dana Ďuricov{\'a} and Nadě{\vz}da Machkov{\'a} and Veronika Hrub{\'a} and Martin Luk{\'a}{\vs} and Katar{\'i}na Mitrov{\'a} and Karin Mal{\'i}{\vc}kov{\'a} and Anita B{\'a}lint and Ferenc Tam{\'a}s Nagy and R. Irem Bor and {\'A}gnes Milassin and Zolt{\'a}n Szepes and K{\'a}roly Palatka and Peter L Lakatos and Milan Luk{\'a}{\vs} and Tam{\'a}s Moln{\'a}r},
  journal={Journal of Crohn's & colitis},
  year={2016},
  volume={10 11},
  pages={1273-1278}
}
INTRODUCTION CT-P13 is the first biosimilar to infliximab that has been approved for the same indications as its originator infliximab. No data are available on the effect of infliximab biosimilar on mucosal healing. The aim of this study was to evaluate the efficacy of CT-P13 induction therapy on mucosal healing in patients with ulcerative colitis [UC]. PATIENTS AND METHODS UC patients, who received CT-P13 therapy from its local introduction at three Hungarian and one Czech inflammatory… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

Similar Papers

Loading similar papers…